



The Special Testing and Research Laboratory's Emerging Trends Program compiled the data for this report through a query of archived seizure and analysis information from drug evidence analyzed by the Drug Enforcement Administration's laboratory system. This data is representative of drug evidence seized and analyzed in the reported time frame. This is not a comprehensive list of all new psychoactive substances and is not representative of all evidence analyzed


by DEA. This data is a quarterly snapshot of the new psychoactive substance market in the United States.

The term new psychoactive substance (NPS) describes a recently emerged drug that may pose a public health threat. This includes synthetic cannabinoids, substituted cathinones, phenethylamines, opioids, tryptamines, benzodiazepines, and a variety of other chemical classes. Due to the recent increase in seizures, fentanyl is also included in this report.

An identification is made when authenticated reference material is available for comparison. When reference material is not available, the drug evidence is identified as "substance unconfirmed". A single unit of drug evidence may have multiple sub-units. For the purposes of this document, each unit of drug evidence counts as one identification regardless of the number of sub-units. Some seized drug evidence contains more than one active ingredient; therefore, more than one identification can be made for a single unit.

SYNTHETIC CANNABINOIDS

THERE WERE **117** SYNTHETIC CANNABINOID IDENTIFICATIONS IN THE FIRST QUARTER OF CY 2017. FUB-AMB ACCOUNTED FOR APPROXIMATELY **43%** OF THE IDENTIFICATIONS. $\backslash \backslash \text{V} - \ddagger \alpha \text{Vu} = \text{u} \# \text{VV}^* \text{"} \text{Q} \backslash \text{Q} \circ \ddagger - \text{k} - \text{Q} - \text{Vu} \text{Q} \text{Q} \text{"} \text{u} = \text{Q} \text{j} \text{y}^* \text{ku} - \text{k}$



There was a significant increase in the number of synthetic cannabinoid identifications, increasing from **31** identifications during the fourth quarter of CY 2016 to **117** identifications in the first quarter of CY 2017 (a **377%** increase).


MAB-CHMINACA = ADB-CHMINACA

TRYPTAMINES

No substituted tryptamines were identified during the reporting period.

OPIOIDS/ ANALGESICS


THERE WERE **230** IDENTIFICATIONS OF FENTANYL, FENTANYL-RELATED SUBSTANCES, AND OTHER SYNTHETIC OPIOIDS. FENTANYL ACCOUNTED FOR APPROXIMATELY **58%** OF THE IDENTIFICATIONS. THE NEXT MOST PROMINENT FENTANYL-RELATED SUBSTANCE, FURANYL FENTANYL, ACCOUNTED FOR **26%** OF THE IDENTIFICATIONS. $\backslash \backslash \text{V} - \ddagger \backslash \text{h} \text{Q} \text{Q} \circ \ddagger - \text{k} - \text{Q} - \text{Vu} \text{Q} \text{Q} \text{"} \text{u} = \text{Q} \text{j} \text{y}^* \text{ku} - \text{k}$. OF THE 134 FENTANYL IDENTIFICATIONS, FENTANYL WAS FOUND AS THE ONLY CONTROLLED SUBSTANCE IN APPROX. **28%** OF THE IDENTIFICATIONS AND WAS FOUND IN COMBINATION WITH HEROIN IN APPROX. **61%** OF THE IDENTIFICATIONS.



Other controlled substances identified with fentanyl this quarter include U-47700, alprazolam, heroin, ketamine, and cocaine.

CATHINONES

THERE WERE **40** CATHINONE IDENTIFICATIONS IN THE FIRST QUARTER OF CY 2017. N-ETHYLPENTYLONE ACCOUNTED FOR APPROXIMATELY **55%** OF THE IDENTIFICATIONS. $\backslash \backslash \text{V} - \ddagger \# \text{u} = \text{Q} \backslash \text{V} - \text{o} \ddagger - \text{k} - \text{Q} - \text{Vu} \text{Q} \text{Q} \text{"} \text{u} = \text{Q} \text{j} \text{y}^* \text{ku} - \text{k}$



PBP = Pyrrolidinobutiophenone
PVP = Pyrrolidinovalerophenone
CEC = Chloroethcathinone

OTHER

There were **2** instances of unconfirmed substances this quarter. There were **7** identifications of etizolam, **2** identifications of dimethylamylamine (DMAA), and **1** identification each of 4-methoxyphenylpiperazine and 5-EAPB.

Questions about this data are welcome and may be directed to the DEA Emerging Trends Program at 703-668-3300 or DEA.Emerging.Trends@usdoj.gov

HALLUCINOGENS

There was **1** identification of **25I-NBOMe** during the reporting period.